1 – 10 of 11
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Axillary clearance and chemotherapy rates in ER+HER2− breast cancer : secondary analysis of the SENOMAC trial
(
- Contribution to journal › Article
-
Mark
Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment : a post-hoc analysis of the randomised, phase 3 SENOMAC trial
(
- Contribution to journal › Article
-
Mark
Prediction of High Nodal Burden in Patients With Sentinel Node-Positive Luminal ERBB2-Negative Breast Cancer
(
- Contribution to journal › Article
-
Mark
Quality assessment of radiotherapy in the prospective randomized SENOMAC trial
(
- Contribution to journal › Article
-
Mark
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
(
- Contribution to journal › Article
- 2022
-
Mark
Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial
(
- Contribution to journal › Article
- 2020
-
Mark
The generalisability of randomised clinical trials : an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer
(
- Contribution to journal › Article
- 2017
-
Mark
Reduced breast cancer mortality after 20+ years of follow-up in the Swedish randomized controlled mammography trials in Malmö, Stockholm, and Göteborg
(
- Contribution to journal › Article
-
Mark
Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection : The randomized controlled SENOMAC trial
(
- Contribution to journal › Article
- 2014
-
Mark
When Is the Deep Inferior Epigastric Artery Flap Indicated for Breast Reconstruction in Patients not Treated With Radiotherapy?
(
- Contribution to journal › Article